1% of oral dose for 30-fold lung exposure and reduced cardiotoxicityA cost-effective, easily accessible, user-friendly potential treatment/prevention option TLC19 utilizes TLC’s existing proprietary ...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to ...
TAIPEI, Taiwan, April 03, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (“TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results